Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Case report

Mild encephalopathy with reversible splenium lesion (MERS) in a patient with COVID-19

Bhavika Kakadia Do, Jaffer Ahmed, Todd Siegal, Tudor G. Jovin, Jesse M. Thon

PII: S0967-5868(20)31346-1
DOI: https://doi.org/10.1016/j.jocn.2020.07.009
Reference: YJOCN 9038

To appear in: Journal of Clinical Neuroscience

Received Date: 2 June 2020
Accepted Date: 5 July 2020

Please cite this article as: B. Kakadia Do, J. Ahmed, T. Siegal, T.G. Jovin, J.M. Thon, Mild encephalopathy with reversible splenium lesion (MERS) in a patient with COVID-19, Journal of Clinical Neuroscience (2020), doi: https://doi.org/10.1016/j.jocn.2020.07.009

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Elsevier Ltd. All rights reserved.
Mild Encephalopathy with Reversible Splenium Lesion (MERS) in a Patient with COVID-19

Bhavika Kakadia DO1, Jaffer Ahmed MD1, Todd Siegal MD2, Tudor G. Jovin MD1, Jesse M. Thon MD1

1 Cooper Neurological Institute, Cooper University Hospital, and Cooper Medical School of Rowan University, Camden, NJ 08103
2 Department of Radiology, Cooper University Hospital, Camden, NJ 08103

HIGHLIGHTS

- Mild encephalopathy with reversible splenium lesion (MERS) is a condition characterized by fever, encephalopathy, and a reversible splenium lesion on brain MRI
- MERS has been previously associated with viral infections, such as the influenza virus, and may result from an immune-mediated response to infection
- MERS has not previously been described in conjunction with COVID-19
- We present a case of a patient with MERS and positive SARS-CoV-2 antibodies, the first reported instance of this neurological complication to the virus.
- MERS should be considered in a patient with the characteristic clinico-radiological syndrome and COVID-19 infection

ABSTRACT

Neurological complications of coronavirus 2019 (COVID-19) are common, and novel manifestations are increasingly being recognized. Mild encephalopathy with reversible splenium lesion (MERS) is a syndrome that has been associated with viral infections, but not previously with COVID-19. In this report, we describe the case of a 69 year-old man who presented with fever and encephalopathy in the setting of a diffusion-restricting splenium lesion, initially mimicking an ischemic stroke. A comprehensive infectious workup revealed positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, and a pro-inflammatory laboratory profile characteristic of COVID-19 infection. His symptoms resolved and the brain MRI findings completely normalized on repeat imaging, consistent with MERS. This case suggests that MERS may manifest as an autoimmune response to SARS-CoV-2 infection and should be considered in a patient with evidence of recent COVID-19 infection and the characteristic MERS clinico-radiological syndrome.

INTRODUCTION

As the COVID-19 pandemic continues, associated neurological complications are being increasingly described. According to an observational study from Wuhan, China, 36.4% of patients infected with SARS-CoV-2 demonstrated neurological manifestations (1). The virus has been linked to several different types of neurological complications, including hyposmia, hypogeusia, encephalitis, headache, neuropathy, and stroke (2). It has been speculated that these manifestations may result from direct viral...
entry into the central nervous system via multiple mechanisms, such as retrograde neuronal migration and hematogenous spread (3). Subsequent passage into neurons is likely mediated by binding to the cellular angiotensin-converting enzyme 2 (ACE2) receptor, which is a known route of cellular entry by both SARS-CoV and SARS-CoV-2 (4). ACE2 is expressed throughout the brain, including in the brainstem, and viral involvement of the brainstem cardiorespiratory centers is thought to play a role in the severe respiratory symptoms experienced by many infected with SARS-CoV-2 (5). In addition to direct neuronal invasion, neurological manifestations of SARS-CoV-2 infection also result from an autoimmune response to the virus. SARS-CoV-2 has been associated with a severe inflammatory response in a subset of patients (6). Additionally, it has been linked with neurological immune-mediated conditions such as Guillain Barre syndrome, acute disseminated encephalomyelitis, and acute hemorrhagic necrotizing encephalopathy (7,8,9).

Mild encephalopathy with reversible splenium lesion (MERS) is a clinico-radiographical condition that is characterized by a reversible lesion isolated to the corpus callosum on magnetic resonance imaging (MRI) (10). Patients with MERS typically present with fever and associated encephalopathy, confusion, and lethargy (10). Other neurological manifestations that have been reported are seizures and behavioral changes (10). MERS has been associated with antiepileptic medication withdrawal, high-altitude exposure, and metabolic disturbances, but it is most commonly associated with infection (11). Here, we describe the case of a patient with MERS and evidence of COVID-19 infection, which has not been previously reported.

CASE PRESENTATION

A 69 year-old man with hypertension and recent visit to Nigeria presented to the hospital with acute-onset encephalopathy and high grade fever. His neurologic exam on presentation was significant for disorientation, inattention, and bradyphrenia without focal deficits.

A metabolic and extensive infectious workup, including serological and CSF testing for pathogens associated with his recent travel, only revealed elevated SARS-CoV-2 IgA and IgG antibodies, suggesting recent exposure. Polymerase chain reaction (PCR) testing of nasopharyngeal samples for SARS-CoV-2 was negative. A lumbar puncture showed normal cerebrospinal fluid (CSF) leukocyte count, protein, and glucose. He had significantly elevated systemic inflammatory markers, including elevated c-reactive protein (CRP) (50.32 mg/dL, ref <0.50), interleukin-6 (18.58 pg/mL, ref <5.00), fibrinogen (>1000 mg/dL, ref 173-430) and d-dimer levels (6.40 ug/mL, ref <0.50). Electroencephalogram (EEG) showed diffuse slowing. Brain MRI revealed a non-enhancing region of restricted diffusion and fluid-attenuated inversion recovery (FLAIR) hyperintensity in the splenium of the corpus callosum (figure 1 a-c). Magnetic resonance angiography (MRA) of the head and neck was unremarkable. An echocardiogram showed new-diagnosis heart failure, with an ejection fraction of <30%. He was treated with anticoagulation given concern for cardioembolism in the setting of heart failure and suspected prothrombotic state. His encephalopathy resolved over the course of two weeks. At that time, a repeat brain MRI showed complete resolution of the corpus callosum lesion (figure 1 d-f), consistent with MERS.

DISCUSSION
In this report, we present a case of mild encephalopathy with reversible splenium lesion in a patient with COVID-19 antibodies and a proinflammatory marker profile that has been associated with SARS-CoV-2 infection (12). His clinical syndrome of fevers and encephalopathy in conjunction with a reversible midline splenium lesion on brain MRI, is characteristic of MERS (13). Typical imaging features of the MERS defining lesion, as noted in this case, are high signal intensity on T2, FLAIR, and diffusion-weighted imaging (DWI) sequences, decreased intensity on apparent diffusion coefficient (ADC) maps, and no contrast enhancement (figure 1). This condition, more commonly seen in Asian populations and children, but also reported in other populations, has been associated with metabolic abnormalities, antiepileptic medications, but most frequently with infections such as influenza virus (13, 14). Although the pathophysiologic mechanism underlying MERS is unknown, it is believed that intramyelinic edema and inflammation within the splenium may be the result of a spontaneously reversible autoimmune response, with complete resolution of clinical and radiographical abnormalities seen in most instances (14, 15).

In our case, such a response to SARS-CoV-2 is suggested by the presence of antibodies to this virus, a pro-inflammatory laboratory profile which has been associated with SARS-CoV-2 infection, including elevated D-dimer, CRP, fibrinogen, and interleukin-6 levels (12), and the absence of other etiologies. This is the first case, to our knowledge, demonstrating that MERS can be a consequence of exposure to the virus. Although presumably an autoimmune response, such as has been recently recognized in other immune-mediated neurological complications of COVID-19 (7,8,9), the exact mechanism(s) by which MERS may result from SARS-CoV-2 are unknown and warrant future study.

CONCLUSION

In summary, we report a case of MERS in a patient with evidence of SARS-CoV-2 infection. To our knowledge, this neurological complication has not been previously described in association with COVID-19. Given what is known about the pathophysiologic mechanism of MERS and the presence of antibodies to SARS-CoV-2 in our patient, we propose that MERS may result from an autoimmune response to the virus. We suggest that MERS should be considered in a patient with encephalopathy and a diffusion-restricting, FLAIR hyperintense lesion in the splenium of the corpus callosum in a patient with testing consistent with recent COVID-19 infection.
Figure 1. A reversible splenium lesion on MRI in a patient with antibodies to SARS-CoV-2. Initial MRI brain showed a midline splenium increased signal on (a) DWI and (b) FLAIR, and decreased signal on (b) ADC sequences. After two weeks, there was complete reversal of these changes on (d) DWI, (e) ADC, and (f) FLAIR sequences.

REFERENCES

1. Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020 doi: 10.1001/jamaneurol.2020.1127.
2. Wu Y, Xu X, Chen Z., et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain, Behavior, and Immunity. 2020 Mar 30. doi: 10.1016/j.bbi.2020.03.031
3. Li Z, Liu T, Yang N, et al. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain [published online ahead of print, 2020 May 4]. Front Med. 2020;1-9. doi:10.1007/s11684-020-0786-5.
4. Zhou Z, Kang H, Li S, Zhao X. Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms [published online ahead of print, 2020 May 26]. J Neurol. 2020;1-6. doi:10.1007/s00415-020-09929-7
5. Steardo L, Steardo L Jr, Zorec R, et al. Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19 [published online ahead of print, 2020 Mar 29]. Acta Physiol (Oxf). 2020;e13473. doi:10.1111/apha.13473

6. Cao, X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol 2020; 20: 269–270. https://doi.org/10.1038/s41577-020-0308-3

7. Sedaghat Z, Karimi N. Guillain Barre syndrome associated with COVID-19 infection: A case report. Journal of Clinical Neuroscience. 2020 Apr 11. doi: 10.1016/j.jocn.2020.04.062.

8. Parsons T, Banks S, Bae C, et al. COVID-19-associated acute disseminated encephalomyelitis (ADEM) [published online ahead of print, 2020 May 30]. J Neurol. 2020;10.1007/s00415-020-09951-9. doi:10.1007/s00415-020-09951-9

9. Poyiadji N, Shahin G, Noujaim D, et al. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI Features [published online ahead of print, 2020 Mar 31]. Radiology. 2020;201187. doi:10.1148/radiol.2020201187

10. Ka A, Britton P, Troedson C, et al. Mild encephalopathy with reversible splenial lesion: an important differential of encephalitis. European Journal of Paediatric Neurology. 2015 Feb 13. doi: 10.1016/j.ejpn.2015.01.011

11. Garcia-Monco JC, Cortina IE, Ferreira E, et al. Reversible splenial lesion syndrome (RESLES): What’s in a name? Journal of Neuroimaging. 2011 Apr. doi: 10.1111/j.1552-6569.2008.00279.x.

12. Connors JM, Levy JH. COVID-19 and Its Implications for Thrombosis and Anticoagulation. Blood. 2020 Apr 27. doi: 10.1182/blood.2020006000.

13. Yuan J, Yang S, Wang S, et al. Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) in adults-a case report and literature review. BMC Neurol 2017; 17: 103–111.

14. Takanashi J, Barkovich AJ, Yamaguchi K, et al. Influenza-Associated Encephalitis/Encephalopathy with a Reversible Lesion in the Splenium of the Corpus Callosum: A Case Report and Literature Review. American Journal of Neuroradiology. 2004; 25 (5): 798-802.

15. Zhu Y, Zheng J, Zhang L, et al. Reversible splenial lesion syndrome associated with encephalitis/encephalopathy presenting with great clinical heterogeneity. BMC Neurol. 2016; 16:49.
There are no known competing financial interests or personal relations that could have appear to influence the work reported in this paper.